Impact of Active and Historical Cancers on the Management and Outcomes of Acute Myocardial Infarction Complicating Cardiogenic Shock.
Cardiogenic shock
cancer
myocardial infarction
outcomes research
Journal
Texas Heart Institute journal
ISSN: 1526-6702
Titre abrégé: Tex Heart Inst J
Pays: United States
ID NLM: 8214622
Informations de publication
Date de publication:
01 09 2022
01 09 2022
Historique:
entrez:
12
10
2022
pubmed:
13
10
2022
medline:
15
10
2022
Statut:
ppublish
Résumé
There are limited data on the outcomes of acute myocardial infarction-cardiogenic shock (AMI-CS) in patients with concomitant cancer. A retrospective cohort of adult AMI-CS admissions was identified from the National Inpatient Sample (2000-2017) and stratified by active cancer, historical cancer, and no cancer. Outcomes of interest included in-hospital mortality, use of coronary angiography, use of percutaneous coronary intervention, do-not-resuscitate status, palliative care use, hospitalization costs, and hospital length of stay. Of the 557,974 AMI-CS admissions during this 18-year period, active and historical cancers were noted in 14,826 (2.6%) and 27,073 (4.8%), respectively. From 2000 to 2017, there was a decline in active cancers (adjusted odds ratio, 0.70 [95% CI, 0.63-0.79]; P < .001) and an increase in historical cancer (adjusted odds ratio, 2.06 [95% CI, 1.89-2.25]; P < .001). Compared with patients with no cancer, patients with active and historical cancer received less-frequent coronary angiography (57%, 67%, and 70%, respectively) and percutaneous coronary intervention (40%, 47%, and 49%%, respectively) and had higher do-not-resuscitate status (13%, 15%, 7%%, respectively) and palliative care use (12%, 10%, 6%%, respectively) (P < .001). Compared with those without cancer, higher in-hospital mortality was found in admissions with active cancer (45.9% vs 37.0%; adjusted odds ratio, 1.29 [95% CI, 1.24-1.34]; P < .001) but not historical cancer (40.1% vs 37.0%; adjusted odds ratio, 1.01 [95% CI, 0.98-1.04]; P = .39). AMI-CS admissions with cancer had a shorter hospitalization duration and lower costs (all P < .001). Concomitant cancer was associated with less use of guideline-directed procedures. Active, but not historical, cancer was associated with higher mortality in patients with AMI-CS.
Sections du résumé
BACKGROUND
There are limited data on the outcomes of acute myocardial infarction-cardiogenic shock (AMI-CS) in patients with concomitant cancer.
METHODS
A retrospective cohort of adult AMI-CS admissions was identified from the National Inpatient Sample (2000-2017) and stratified by active cancer, historical cancer, and no cancer. Outcomes of interest included in-hospital mortality, use of coronary angiography, use of percutaneous coronary intervention, do-not-resuscitate status, palliative care use, hospitalization costs, and hospital length of stay.
RESULTS
Of the 557,974 AMI-CS admissions during this 18-year period, active and historical cancers were noted in 14,826 (2.6%) and 27,073 (4.8%), respectively. From 2000 to 2017, there was a decline in active cancers (adjusted odds ratio, 0.70 [95% CI, 0.63-0.79]; P < .001) and an increase in historical cancer (adjusted odds ratio, 2.06 [95% CI, 1.89-2.25]; P < .001). Compared with patients with no cancer, patients with active and historical cancer received less-frequent coronary angiography (57%, 67%, and 70%, respectively) and percutaneous coronary intervention (40%, 47%, and 49%%, respectively) and had higher do-not-resuscitate status (13%, 15%, 7%%, respectively) and palliative care use (12%, 10%, 6%%, respectively) (P < .001). Compared with those without cancer, higher in-hospital mortality was found in admissions with active cancer (45.9% vs 37.0%; adjusted odds ratio, 1.29 [95% CI, 1.24-1.34]; P < .001) but not historical cancer (40.1% vs 37.0%; adjusted odds ratio, 1.01 [95% CI, 0.98-1.04]; P = .39). AMI-CS admissions with cancer had a shorter hospitalization duration and lower costs (all P < .001).
CONCLUSION
Concomitant cancer was associated with less use of guideline-directed procedures. Active, but not historical, cancer was associated with higher mortality in patients with AMI-CS.
Identifiants
pubmed: 36223249
pii: 487440
doi: 10.14503/THIJ-21-7598
pmc: PMC9632367
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2022 by the Texas Heart® Institute, Houston.
Références
Eur Heart J Acute Cardiovasc Care. 2018 Oct;7(7):639-645
pubmed: 28927294
Medicine (Baltimore). 2020 Jan;99(5):e18972
pubmed: 32000427
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
J Am Heart Assoc. 2015 Jan 05;4(1):e001462
pubmed: 25559014
J Am Heart Assoc. 2020 Feb 18;9(4):e014383
pubmed: 32067596
Coron Artery Dis. 2019 Aug;30(5):332-338
pubmed: 30883428
Resuscitation. 2020 Oct;155:55-64
pubmed: 32755665
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
J Clin Med. 2020 Nov 18;9(11):
pubmed: 33218121
Am J Cardiol. 2018 Nov 1;122(9):1465-1470
pubmed: 30180958
J Am Heart Assoc. 2019 Aug 6;8(15):e011954
pubmed: 31315497
Catheter Cardiovasc Interv. 2016 Apr;87(5):E202-23
pubmed: 26756277
Circulation. 2016 Mar 15;133(11):1104-14
pubmed: 26976915
Am J Cardiovasc Drugs. 2018 Oct;18(5):361-372
pubmed: 29931556
Eur J Heart Fail. 2017 Oct;19(10):1242-1254
pubmed: 28463462
Heart Fail Rev. 2019 Nov;24(6):997-1004
pubmed: 31273537
Resuscitation. 2019 Sep;142:30-37
pubmed: 31310845
Eur Heart J. 2020 Jun 14;41(23):2183-2193
pubmed: 31800032
Circulation. 2008 Feb 5;117(5):686-97
pubmed: 18250279
Int J Cardiol. 2019 Jan 15;275:6-12
pubmed: 30318297
BMC Med Res Methodol. 2015 Mar 20;15:23
pubmed: 25888061
J Am Coll Cardiol. 2019 Apr 16;73(14):1781-1791
pubmed: 30975295
J Am Coll Cardiol. 2016 Sep 6;68(10):1143-4
pubmed: 27585514
Am J Cardiol. 2017 Dec 15;120(12):2284-2288
pubmed: 29096885
J Am Heart Assoc. 2014 Jan 13;3(1):e000590
pubmed: 24419737
Eur J Heart Fail. 2017 Feb;19(2):192-200
pubmed: 27709722
Am J Cardiol. 2013 Dec 15;112(12):1867-72
pubmed: 24063839
Front Cardiovasc Med. 2019 May 17;6:57
pubmed: 31157239
J Cancer Res Clin Oncol. 2016 Feb;142(2):471-9
pubmed: 26498773
JAMA. 2017 Nov 28;318(20):2011-2018
pubmed: 29183077